Dallas, Texas 04/17/2014 (ustradevoice) - One of the main reasons, analysts and pundits say, why Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has not had success with its FDA-approved weight management drug known as Belviq, is lack of awareness.
That being the case, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) seems to have come to the realization that unless it takes proactive steps to expand the market share of its anti-obesity drug Belviq, it might as well miss out on a great opportunity.
Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at: http://www.investor-edge.com/905-register On Monday, shares in Arena Pharmaceuticals Inc. gained 2.57% to close the day at $6.38. The stock recorded a ...
Arena (ARNA) and its marketing partner Eisai (OTCPK:ESALY) recently announced a major new stage in commercialization strategy and promotional mix that I believe could be the tipping point for a significant upward inflection in BELVIQ sales.
Sales of the Arena Pharmaceuticals (ARNA) anti-obesity drug Belviq have closed out the quarter on a positive note. Sales improved throughout the quarter and are pacing well ahead of the previous quarter.
It is certainly an interesting time to be an investor in Arena Pharmaceuticals (ARNA). The company is about 10 months into its launch of the anti-obesity drug Belviq and the equity has taken several lumps along the way.